Melbourne Uni cuts deal with Janssen-Cilag to research respiratory infection drug

By Dylan Bushell-Embling
Monday, 29 October, 2012

The University of Melbourne has agreed to collaborate with Janssen-Cilag on potential new-generation treatments for acute respiratory infections.

Through the agreement, the university will receive research funding to explore the potential for new early-stage drug candidates.

The arrangement was facilitated by university's commercial engagement company, UoM Commercial.

University of Melbourne deputy vice-chancellor Professor James McCluskey said the agreement reflects the desire for the university's research “to be translated into impact, and recognises the importance of collaboration with the pharmaceutical industry to achieve this goal.”

He said acute respiratory infections are the most common causes of illness and mortality in children and adults worldwide.

Janssen-Cilag is the Australian subsidiary of the Janssen Pharmaceutical Group, which is itself part of Johnson & Johnson.

Word of the arrangement comes weeks after the university revealed its researchers had been awarded more than $89 million in grants from the $652 million National Health and Medical Research Council (NHMRC) pool.

The funding covers a number of projects, including research into new therapies for ovarian clear cell cancer, autism and inflammatory pain.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd